Cancer Diagnostics · global
Waiting Two More Days to Scan: GTH Evaluates Investment in Zirconium-89 Prostate Cancer Imaging Startup
When PSA signals recurrence but imaging cannot locate a lesion, delaying the scan may offer another clue. Zirnostics’ zirconium-89 tracer technology has drawn GTH’s interest in a potential equity investment, but preliminary lesion detection findings remain some distance from marketing authorization and proof of treatment benefit.
After prostate cancer treatment, prostate-specific antigen (PSA) in the blood may signal recurrence before imaging can locate a lesion. This gap makes it difficult to precisely target subsequent treatment and is a shortcoming that a new generation of radioactive tracers aims to address. German Tech Holding (GTH) announced on October 7 that it is evaluating the acquisition of a 10% stake in German startup Zirnostics GmbH to support a zirconium-89-labeled prostate cancer imaging technology that allows scanning several days after injection.
The investment has not been finalized. In an ad hoc disclosure, GTH said it was still evaluating financing options for acquiring the stake and did not disclose a transaction value. A more detailed press release issued the same day stated that the technology originated with Professor Samer Ezziddin’s research team at Saarland University Hospital in Germany. Zirnostics, newly established to advance commercialization, is based at Science Park Saar in Saarbrücken, with Christoph Gerlinger serving as managing director.
The key to the technology is delaying image acquisition. The tracer targets prostate-specific membrane antigen (PSMA), which is often highly expressed by prostate cancer cells, with the signal then visualized using positron emission tomography combined with computed tomography (PET/CT). Zirconium-89 has a half-life of approximately 78 hours, allowing scanning after background signals in normal tissue have gradually declined, making lesions easier to see. GTH claims that tumor-to-background contrast can increase by up to 100-fold; this is a claim about image contrast and cannot be interpreted as a 100-fold increase in diagnostic accuracy or the ability to detect cancer.
Research has provided preliminary clinical clues. A retrospective analysis published in 2023 included 23 patients with biochemical recurrence after prostate cancer surgery whose previous gallium-68 PSMA-PET/CT scans had shown no lesions. After switching to a zirconium-89 tracer, 18 had suspicious lesions on images acquired 24 or 48 hours after injection. However, not all suspicious imaging findings had pathological confirmation, so the results support further validation but are not yet sufficient to establish overall diagnostic accuracy.
Another single-center feasibility study, published online in April 2026, analyzed 65 patients with PSA levels no higher than 0.2 ng/mL. Scans performed 48 hours after injection showed at least one suspicious lesion in 47 patients, a positivity rate of 72.3%. GTH also cited a positivity rate of approximately 30% for conventional tracers from another multicenter study as a comparison; the two studies involved different patient populations, so they cannot be used to directly calculate the magnitude of zirconium-89’s advantage. Imaging positivity rates also do not equate to fully validated sensitivity.
These findings suggest a potential role in helping locate early recurrence, particularly lesions that are difficult to identify with existing imaging, and providing additional information for subsequent treatment planning. However, small, single-center studies still cannot readily answer how many of the additional imaging findings truly represent cancer or whether they can improve long-term disease control. The scheduling implications of delayed scanning, along with the balance between radiation exposure and diagnostic benefit, also need to be included in a more comprehensive clinical evaluation.
GTH said the method already has several years of clinical use, but commercialization still requires marketing authorization in each market and additional clinical trials. For Zirnostics, the next step is to turn promising lesion images into reproducible evidence sufficient to support regulatory review; for potential investors, the announcement remains an equity investment opportunity that is still under evaluation.